Tag:
Crestor
Latest Headlines
Latest Headlines
With new plant, Ranbaxy back in force in North America
After a four-year stint of being unable to ship drugs from its plants in India to the U.S. and Canada, Ranbaxy Laboratories is returning in a big way.
Health plans sue Big Pharma over co-pay coupons
Pharma's co-pay discounts have their fans--patients, certainly, but they also have their detractors.
How worrisome is the statin-diabetes link?
The FDA's cautionary word on statin use has stirred up a back-and-forth risk-benefits debate. When the agency announced last week that it would highlight the risk of Type 2 diabetes on the cholesterol drugs' labels, some prominent heart doctors issued their own warnings: Don't worry too much about that risk. For most patients, the heart benefits of statins outweigh the "small" risk of developing diabetes.
FDA flags diabetes risks with statin drugs
Big-selling cholesterol drugs got new warnings on their labels, but the cautionary language about blood sugar and memory loss isn't expected to diminish their popularity much.
Can AstraZeneca continue to swear off major M&A?
Can AstraZeneca ( $AZN ) CEO David Brennan stick to his no-megadeals diet? Analysts are beginning to wonder, says Bloomberg, now that three of the company's promising drug candidates have stumbled. The
Co-pay cards prompt CVS to toss drugs off formulary
It had to happen eventually: A pharmacy benefits manager is striking back at co-pay coupons. As The Wall Street Journal reports, CVS Caremark's PBM is recommending that customers stop covering 34
AZ's Crestor scored points, but didn't beat Lipitor
AstraZeneca's press release on the SATURN trial is an object lesson in how to spin a study that didn't turn out as expected: Focus on the positive. The company announced SATURN showed "intensive"
AZ launches Crestor co-pay card to battle Lipitor copies
Joining the growing number of drugmakers using discount cards and coupons to retain patients, AstraZeneca ( $AZN ) has launched a co-pay help card for its statin drug Crestor . The cholesterol remedy
AZ settles another Seroquel patent suit, defends Crestor
Two big questions about AstraZeneca's ( $AZN ) intellectual property today: Has the domino effect from AstraZeneca's Seroquel XR patent settlement begun? And will AstraZeneca persuade an appeals court
AstraZeneca's Crestor fails to best Lipitor in study
AstraZeneca ( $AZN ) just lost a potential marketing edge for Crestor. In trial results announced today, the statin drug failed to best Lipitor at clearing clogged arteries, at least in a statistically
